GlassScriptPhysician profile
Kimberly A Adams
NPI 1659399269
$51,206.23
in general payments reported to CMS, 2019-2025
59 companies · $4,691 in 2025
The $4,691 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $682 · 2021: $2,412 · 2022: $1,900 · 2023: $32K · 2024: $7,549 · 2025: $4,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Food and Beverage: $6,495 · Travel and Lodging: $6,187 · Education: $11.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,350.00 |
| Food and Beverage | $6,495.04 |
| Travel and Lodging | $6,186.69 |
| Education | $11.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36,284.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Intuitive Surgical, INC. | $2,372.15 | 2025 | |
| Abbvie INC. | $1,893.42 | 2020-2025 | Vraylar, Ubrelvy, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,462.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,186.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $968.98 | 2019-2025 | Repatha, Otezla, Otezla |
| Intra-Sana Laboratories | $898.91 | 2022-2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Pfizer INC. | $894.39 | 2019-2025 | |
| Abbott Laboratories | $808.08 | 2021-2024 | Cardiomems, Freestyle Libre 2, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $544.63 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $469.00 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.68 | 2022-2025 | |
| Astellas Pharma US INC | $266.68 | 2019-2025 | Veozah |
| Allergan, INC. | $235.83 | 2019-2020 | |
| Nevro Corp. | $188.92 | 2021 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.